Cofinimmo Valuation

Is COFB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of COFB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: COFB (€56.3) is trading below our estimate of fair value (€87.6)

Significantly Below Fair Value: COFB is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for COFB?

Key metric: As COFB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for COFB. This is calculated by dividing COFB's market cap by their current revenue.
What is COFB's PS Ratio?
PS Ratio5.4x
Sales€394.00m
Market Cap€2.14b

Price to Sales Ratio vs Peers

How does COFB's PS Ratio compare to its peers?

The above table shows the PS ratio for COFB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.9x
AED Aedifica/SA
8x3.7%€2.7b
MONT Montea Comm. VA
11.3x8.9%€1.5b
SHUR Shurgard Self Storage
10.3x10.9%€3.8b
WDP Warehouses De Pauw
10.3x3.2%€4.7b
COFB Cofinimmo
5.4x-0.1%€2.1b

Price-To-Sales vs Peers: COFB is good value based on its Price-To-Sales Ratio (5.4x) compared to the peer average (9.9x).


Price to Sales Ratio vs Industry

How does COFB's PS Ratio compare vs other companies in the Global Health Care REITs Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
COFB 5.4xIndustry Avg. 6.5xNo. of Companies6PS03.26.49.612.816+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: COFB is good value based on its Price-To-Sales Ratio (5.4x) compared to the Global Health Care REITs industry average (6.7x).


Price to Sales Ratio vs Fair Ratio

What is COFB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

COFB PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.4x
Fair PS Ratio7.4x

Price-To-Sales vs Fair Ratio: COFB is good value based on its Price-To-Sales Ratio (5.4x) compared to the estimated Fair Price-To-Sales Ratio (7.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst COFB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€56.30
€71.50
+27.0%
6.8%€76.50€60.00n/a14
Nov ’25€58.00
€71.50
+23.3%
6.8%€76.50€60.00n/a14
Oct ’25€66.70
€72.07
+8.1%
6.3%€77.00€60.00n/a14
Sep ’25€61.75
€70.36
+13.9%
7.0%€77.00€60.00n/a14
Aug ’25€60.80
€71.14
+17.0%
8.1%€80.00€60.00n/a14
Jul ’25€56.65
€72.44
+27.9%
6.7%€80.00€60.00n/a14
Jun ’25€60.80
€72.31
+18.9%
8.2%€80.00€60.00n/a14
May ’25€62.30
€72.39
+16.2%
8.2%€80.00€60.00n/a14
Apr ’25€60.65
€72.74
+19.9%
8.2%€80.00€60.00n/a14
Mar ’25€57.65
€73.53
+27.5%
7.1%€80.00€60.00n/a14
Feb ’25€65.15
€74.03
+13.6%
7.2%€82.00€60.00n/a14
Jan ’25€71.40
€74.25
+4.0%
7.7%€85.00€62.00n/a14
Dec ’24€65.45
€74.89
+14.4%
8.9%€87.00€62.00n/a14
Nov ’24€59.70
€75.46
+26.4%
9.6%€87.00€62.00€58.0013
Oct ’24€64.90
€82.27
+26.8%
12.7%€102.00€68.00€66.7013
Sep ’24€70.80
€86.69
+22.4%
12.9%€105.00€68.00€61.7513
Aug ’24€70.85
€89.96
+27.0%
11.6%€105.00€68.00€60.8013
Jul ’24€68.80
€90.86
+32.1%
9.3%€105.00€75.00€56.6511
Jun ’24€73.25
€91.77
+25.3%
10.1%€105.00€75.00€60.8011
May ’24€86.65
€93.05
+7.4%
11.5%€110.00€75.00€62.3011
Apr ’24€81.55
€93.05
+14.1%
11.5%€110.00€75.00€60.6511
Mar ’24€84.00
€95.18
+13.3%
10.9%€110.00€75.00€57.6511
Feb ’24€84.70
€101.09
+19.4%
20.2%€155.00€75.00€65.1511
Jan ’24€83.70
€110.59
+32.1%
20.4%€155.00€80.00€71.4011
Dec ’23€83.10
€110.95
+33.5%
20.2%€155.00€80.00€65.4511
Nov ’23€87.10
€122.50
+40.6%
16.8%€155.00€87.00€59.7011

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies